Pan Zhi, Tian Hongjun, Fang Tao, Liu Zhidong, Liu Xiangdong, Dou Guangqian, Huang Guoyong, Zhang Zhenqing, Chen Guangdong, Wang Wenqiang, Zhuo Chuanjun
Key Laboratory of Genetic Psychiatry, Wenzhou Seventh People Hospital, Wenzhou, China.
Key Laboratory of Real Time Tracing of Brain Circuits of Neurology and Psychiatry, Nankai University Affiliated Tianjin Fourth Center Hospital, Tianjin Medical University Affiliated Tianjin Fourth Center Hospital, Tianjin Fourth Center Hospital, Tianjin, China.
Front Psychiatry. 2022 Mar 18;13:771950. doi: 10.3389/fpsyt.2022.771950. eCollection 2022.
Depressive disorders are a severe psychiatric and social problem that affect more than 4% of the global population. Depressive disorders have explicit hereditary characteristics; however, the precise driving genetic force behind these disorders has not yet been clearly illustrated. In the present study, we recruited a three-generation Chinese pedigree in which 5 of 17 members had long-term depression. We conducted whole-exome sequencing to identify the genetic mutation profiles of the family, and a list of susceptible genetic variations that were highly associated with depression onset was revealed via multiple omics analysis. In particular, a non-synonymous single nucleotide variation in the oxoglutarate dehydrogenase-like () gene, rs2293239 (p.Asn725Ser), was identified as one of the major driving genetic forces for depression onset in the family. This variant causes an important conformational change in the transketolase domain of , thus reducing its binding affinity with the cofactor thiamine pyrophosphate and eventually resulting in the abnormal accumulation of glutamate in the brain. Brain imaging analysis further linked the rs2293239 variant with an enlarged amygdala and cerebellum in depressive family members. In summary, the present study enhances the current genetic understanding of depressive disorders. It also provides new options for prioritizing better clinical therapeutic regimens, as well as identifying a new protein target for the design of highly specific drugs to treat depressive disorders.
抑郁症是一个严重的精神和社会问题,影响着全球超过4%的人口。抑郁症具有明确的遗传特征;然而,这些疾病背后确切的驱动遗传因素尚未得到清晰阐释。在本研究中,我们招募了一个三代中国家系,其中17名成员中有5名患有长期抑郁症。我们进行了全外显子组测序以确定该家族的基因突变谱,并通过多组学分析揭示了一系列与抑郁症发病高度相关的易感基因变异。特别地,在氧代戊二酸脱氢酶样()基因中的一个非同义单核苷酸变异rs2293239(p.Asn725Ser)被确定为该家族抑郁症发病的主要驱动遗传因素之一。这种变异导致了转酮醇酶结构域的重要构象变化,从而降低了其与辅因子硫胺素焦磷酸的结合亲和力,最终导致大脑中谷氨酸异常积累。脑成像分析进一步将rs2293239变异与抑郁家族成员中杏仁核和小脑增大联系起来。总之,本研究增进了当前对抑郁症的遗传学理解。它还为优先选择更好的临床治疗方案提供了新的选择,以及为设计治疗抑郁症的高特异性药物确定了新的蛋白质靶点。